$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

$lgnd Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000088616318000113 Filed on August 08, 2018

Income Statement

Concept	2018 Q2	2017 Q2	2016 Q4
Revenue	$90.04M	$28.00M	$38.19M
YoY Change	221.64%	43.41%	80.18%
Cost Of Revenue	$1.134M	$903.0K	$2.900M
YoY Change	25.58%	25.42%	229.55%
Gross Profit	$88.91M	$27.09M	$35.29M
YoY Change	228.17%	44.1%	73.76%
Gross Profit Margin	98.74%	96.77%	92.42%
Selling, General & Admin	$9.290M	$6.550M	$6.630M
YoY Change	41.83%	-4.52%	7.11%
% of Gross Profit	10.45%	24.18%	18.79%
Research & Development	$6.135M	$4.822M	$6.410M
YoY Change	27.23%	-1.87%	123.34%
% of Gross Profit	6.9%	17.8%	18.16%
Depreciation & Amortization	$3.000M	$2.600M	$3.000M
YoY Change	15.38%	2500.0%	328.57%
% of Gross Profit	3.37%	9.6%	8.5%
Operating Expenses	$6.135M	$4.822M	$15.76M
YoY Change	27.23%	-1.87%	73.76%
Operating Profit	$70.18M	$13.02M	$19.53M
YoY Change	439.19%	227.92%	73.75%
Interest Expense	$13.45M	$3.341M	-$12.00M
YoY Change	302.69%	9.51%	138.57%
% of Operating Profit	19.17%	25.67%	-61.44%
Other Income/Expense, Net	$25.40M	-$4.715M	-$130.0K
YoY Change	-638.79%	-66.37%	-18.75%
Pretax Income	$95.58M	$8.300M	$7.230M
YoY Change	1051.55%	-182.58%	24.01%
Income Tax	$22.42M	$22.42M	$10.35M
% Of Pretax Income	23.46%	270.11%	143.21%
Net Earnings	$73.16M	$73.16M	-$3.125M
YoY Change	0.0%	-1285.74%	-149.28%
Net Earnings / Revenue	81.25%	261.33%	-8.18%
Basic Earnings Per Share	$3.45	$3.45	$0.15
Diluted Earnings Per Share	$2.99	$2.99	$0.15
COMMON SHARES
Basic Shares Outstanding	21.21M shares	21.21M shares	20.90M shares
Diluted Shares Outstanding	24.44M shares	24.44M shares	20.90M shares

Balance Sheet

Concept	2018 Q2	2017 Q2	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.017B	$172.6M	$141.0M
YoY Change	489.05%	61.31%	-29.57%
Cash & Equivalents	$151.5M	$60.22M	$18.75M
Short-Term Investments	$865.3M	$112.4M	$122.3M
Other Short-Term Assets	$12.82M	$1.072M	$2.175M
YoY Change	1095.62%	-58.8%	13.99%
Inventory	$9.520M	$6.809M	$1.923M
Prepaid Expenses			$1.864M
Receivables	$42.00M	$13.50M	$14.70M
Other Receivables	$0.00	$3.200M	$3.500M
Total Short-Term Assets	$1.480B	$197.2M	$163.1M
YoY Change	650.83%	55.79%	-24.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.187M	$1.875M	$1.819M
YoY Change	123.31%	58.76%	388.98%
Goodwill	$85.96M	$72.21M	$72.21M
YoY Change	19.05%	-0.21%	490.02%
Intangibles	$222.0M	$199.3M	$204.7M
YoY Change	11.4%	-5.17%	323.41%
Long-Term Investments	$0.00	$6.014M	$8.345M
YoY Change	-100.0%	-67.9%	-71.93%
Other Assets	$642.0K	$1.668M	$1.744M
YoY Change	-61.51%	176.62%	6359.26%
Total Long-Term Assets	$377.8M	$442.8M	$438.5M
YoY Change	-14.69%	-9.67%	52.08%
TOTAL ASSETS
Total Short-Term Assets	$1.480B	$197.2M	$163.1M
Total Long-Term Assets	$377.8M	$442.8M	$438.5M
Total Assets	$1.858B	$640.0M	$601.6M
YoY Change	190.35%	3.77%	19.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.682M	$1.799M	$2.734M
YoY Change	49.08%	-22.99%	-33.04%
Accrued Expenses	$9.312M	$5.325M	$6.397M
YoY Change	74.87%	7.55%	18.35%
Deferred Revenue	$1.700M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$210.4M	$218.6M	$212.9M
YoY Change	-3.75%	5.3%	4.93%
Total Short-Term Liabilities	$632.9M	$225.8M	$227.1M
YoY Change	180.22%	2.49%	1.93%
LONG-TERM LIABILITIES
Long-Term Debt	$595.9M	$24.30M	$29.60M
YoY Change	2352.26%	-29.97%	-25.25%
Other Long-Term Liabilities	$1.563M	$915.0K	$687.0K
YoY Change	70.82%	129.9%	131.31%
Total Long-Term Liabilities	$1.563M	$915.0K	$687.0K
YoY Change	70.82%	129.9%	131.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$632.9M	$225.8M	$227.1M
Total Long-Term Liabilities	$1.563M	$915.0K	$687.0K
Total Liabilities	$1.238B	$230.6M	$230.7M
YoY Change	437.03%	2.55%	2.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$254.2M	-$402.3M	-$431.1M
YoY Change	-36.81%	0.29%	0.38%
Common Stock	$21.00K	$21.00K	$21.00K
YoY Change	0.0%	0.0%	5.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$619.8M	$385.1M	$341.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.858B	$640.0M	$601.6M
YoY Change	190.35%	3.77%	19.58%

Cashflow Statement

Concept	2018 Q2	2017 Q2	2016 Q4
OPERATING ACTIVITIES
Net Income	$73.16M	$73.16M	-$3.125M
YoY Change	0.0%	-1285.74%	-149.28%
Depreciation, Depletion And Amortization	$3.000M	$2.600M	$3.000M
YoY Change	15.38%	2500.0%	328.57%
Cash From Operating Activities	$73.60M	$15.40M	$21.00M
YoY Change	377.92%	48.08%	54.41%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$100.0K	$0.00
YoY Change	100.0%	-99.46%
Acquisitions
YoY Change
Other Investing Activities	-$586.6M	$34.30M	-$86.60M
YoY Change	-1810.2%	-6.54%	659.65%
Cash From Investing Activities	-$586.7M	$34.20M	-$86.70M
YoY Change	-1815.5%	86.89%	653.91%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	613.6M	0.000	-2.100M
YoY Change		-100.0%	-240.0%
NET CHANGE
Cash From Operating Activities	73.60M	15.40M	21.00M
Cash From Investing Activities	-586.7M	34.20M	-86.70M
Cash From Financing Activities	613.6M	0.000	-2.100M
Net Change In Cash	100.5M	49.60M	-67.80M
YoY Change	102.62%	64.24%	-1983.33%
FREE CASH FLOW
Cash From Operating Activities	$73.60M	$15.40M	$21.00M
Capital Expenditures	-$200.0K	-$100.0K	$0.00
Free Cash Flow	$73.80M	$15.50M	$21.00M
YoY Change	376.13%	-46.37%	54.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q2	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	8146000	USD
	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-966000	USD
	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-2730000	USD
CY2018Q1	lgnd	Paymentsto Contingent Value Right Holdersand Other Contingency Payments Investing Activities PaymentstoContingentValueRightHoldersandOtherContingencyPaymentsInvestingActivities	1000000	USD
	lgnd	Proceedsfrom Repaymentof Commercial License Rights ProceedsfromRepaymentofCommercialLicenseRights	2859000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000886163
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21103841	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	lgnd	Proceedsfrom Repaymentof Commercial License Rights ProceedsfromRepaymentofCommercialLicenseRights	0	USD
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	5420000	USD
	lgnd	Revenue Recognition Milestone Method Third Party Portionof Milestone Payment Received RevenueRecognitionMilestoneMethodThirdPartyPortionofMilestonePaymentReceived	3000000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2259000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2682000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	430000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	367000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	954000	USD
CY2018Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2245000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2486000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-151000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	66000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	798205000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	132000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	285000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	874183000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	4624000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	10669000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	4812000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	9367000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	237021000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	1480470000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5720000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15455000	USD
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3811813	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3761440	shares
	lgnd	Accrued Inventory Purchases AccruedInventoryPurchases	752000	USD
CY2017Q4	lgnd	Commercial License Rights CommercialLicenseRights	19526000	USD
CY2018Q2	lgnd	Commercial License Rights CommercialLicenseRights	20437000	USD
	dei	Entity Registrant Name EntityRegistrantName	LIGAND PHARMACEUTICALS INC
	lgnd	Accrued Inventory Purchases AccruedInventoryPurchases	0	USD
CY2017Q4	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	4703000	USD
CY2018Q2	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	7495000	USD
	lgnd	Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant	-77000	USD
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	0	USD
	lgnd	Increase Decreasein Fair Valueof Convertible Debt Receivableand Warrant IncreaseDecreaseinFairValueofConvertibleDebtReceivableandWarrant	8450000	USD
CY2017Q4	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	9258000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7377000	USD
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	1000000	USD
	lgnd	Revenue Recognition Milestone Method Milestone Payment Received RevenueRecognitionMilestoneMethodMilestonePaymentReceived	4600000	USD
	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	4998000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9312000	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2091908	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1120156	shares
	us-gaap	Payment For Contingent Consideration Liability Operating Activities PaymentForContingentConsiderationLiabilityOperatingActivities	0	USD
CY2017Q4	us-gaap	Assets Assets	671021000	USD
CY2018Q2	us-gaap	Assets Assets	1858284000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	188764000	USD
	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	0	USD
CY2018Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	877560000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1695000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1524000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	182000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	262000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	179528000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	804206000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	181041000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	805468000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18752000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60223000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20620000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151459000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	41471000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	130839000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21148665	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21095174	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21148665	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21095174	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	6012000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	11453000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	73295000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	118427000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2018Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1700000	USD
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1600000	USD
CY2017Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	224529000	USD
CY2018Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	210370000	USD
CY2017Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		USD
CY2018Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	595912000	USD
CY2017Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	903000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1244000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1134000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1922000	USD
CY2017Q2	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	2706000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	199000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	6584000	USD
CY2017Q4	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	18859000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	3305000	USD
CY2018Q2	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	0	USD
CY2018Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	401291000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	84422000	USD
CY2018Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	44586000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5564000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6013000	USD
CY2017Q4	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	0	USD
CY2018Q2	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	399409000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.53
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	5.58
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.99
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.81
CY2017Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.27
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.23
CY2018Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.23
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.22
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4085000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3166000	USD
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	6438000	USD
CY2018Q2	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2017Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	0	USD
CY2018Q2	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	59796000	USD
CY2017Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	-1400000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	-2406000	USD
CY2018Q2	us-gaap	Gain Loss On Investments GainLossOnInvestments	39963000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	61808000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6549000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13872000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9294000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16938000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	85959000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	85961000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	8300000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	14493000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	95579000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	150893000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2330000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	53689000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2242000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3356000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22419000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32452000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2056000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	368000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1263000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16405000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-3224000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-32263000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4286000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4395000	USD
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	981807	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	835329	shares
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1079702	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1010505	shares
CY2018Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1051852	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1385475	shares
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	967533	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	961021	shares
CY2018Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1132781	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1126196	shares
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	228584000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	222001000	USD
CY2017Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	314543000	USD
CY2018Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	307962000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	3341000	USD
	us-gaap	Interest Expense InterestExpense	6638000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	13454000	USD
	us-gaap	Interest Expense InterestExpense	16933000	USD
	us-gaap	Interest Paid InterestPaid	919000	USD
	us-gaap	Interest Paid InterestPaid	919000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	396000	USD
CY2018Q2	us-gaap	Interest Payable Current InterestPayableCurrent	468000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	4373000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	9520000	USD
CY2017Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	481000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	835000	USD
CY2018Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2762000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	3637000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	252374000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	1238471000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	671021000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1858284000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	238868000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	632850000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	13961000	USD
CY2018Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	11800000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	3434000	USD
	us-gaap	Net Income Loss NetIncomeLoss	118441000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4715000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8740000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	73160000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1672000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	616753000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13533000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-620319000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	29610000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	134405000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	6058000	USD
	us-gaap	Net Income Loss NetIncomeLoss	11137000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25404000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	43677000	USD
CY2017Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14980000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	34031000	USD
CY2018Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	19868000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	38984000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	13015000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	23233000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	70175000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	107216000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1512000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3066000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5391000	USD
CY2018Q2	us-gaap	Other Assets Current OtherAssetsCurrent	12817000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4859000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	642000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	90000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	24000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	135000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-14000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	136000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-292000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4248000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1563000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	31571000	USD
	us-gaap	Other Noncash Income OtherNoncashIncome	0	USD
	us-gaap	Other Noncash Income OtherNoncashIncome	31571000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-455000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-531000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3867000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4835000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	52727000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	140250000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	416000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	51887000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	124282000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	745783000	USD
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	3914000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	16900000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4042000	USD
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	90000000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	110175000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	750000000	USD
	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	0	USD
	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	32707000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	83268000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	12791000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2370000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11849000	USD
	us-gaap	Profit Loss ProfitLoss	11137000	USD
	us-gaap	Profit Loss ProfitLoss	118441000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4212000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4187000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	25596000	USD
CY2018Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	42001000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	21785000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4822000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13495000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6135000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13540000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400924000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-254240000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	27995000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	57264000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	90043000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	146200000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10669000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9367000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.47
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.36
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.34
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.028
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.028
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1400000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	41.38
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	12228	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	224312	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1876332	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1899418	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	53.17
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	64.81
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	61.78
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	104.54
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	161.83
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y9M18D
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M12D
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	181041000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	805468000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	188998	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	399788000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	619813000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	24000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23216000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23215900	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23117164	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23117000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24438000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24437922	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24618249	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24618000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21012611	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20974738	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21211877	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21209467	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21013000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20975000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21212000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21209000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	156054	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	170900	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	59605	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	61782	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reclassifications</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain amounts in the prior period combined financial statements have been reclassified to conform with the current period presentation.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000886163-18-000113-index-headers.html	Edgar Link	pending
0000886163-18-000113-index.html	Edgar Link	pending
0000886163-18-000113.txt	Edgar Link	pending
0000886163-18-000113-xbrl.zip	Edgar Link	pending
a1014redlineamendmentnum.htm	Edgar Link	pending
a1014redlineamendmentnum001.jpg	Edgar Link	pending
a1014redlineamendmentnum002.jpg	Edgar Link	pending
a1014redlineamendmentnum003.jpg	Edgar Link	pending
a1014redlineamendmentnum004.jpg	Edgar Link	pending
a1014redlineamendmentnum005.jpg	Edgar Link	pending
a1014redlineamendmentnum006.jpg	Edgar Link	pending
a1014redlineamendmentnum007.jpg	Edgar Link	pending
a1014redlineamendmentnum008.jpg	Edgar Link	pending
a1014redlineamendmentnum009.jpg	Edgar Link	pending
a1014redlineamendmentnum010.jpg	Edgar Link	pending
a1014redlineamendmentnum011.jpg	Edgar Link	pending
a1014redlineamendmentnum012.jpg	Edgar Link	pending
a1014redlineamendmentnum013.jpg	Edgar Link	pending
a1014redlineamendmentnum014.jpg	Edgar Link	pending
a1014redlineamendmentnum015.jpg	Edgar Link	pending
a1014redlineamendmentnum016.jpg	Edgar Link	pending
a1014redlineamendmentnum017.jpg	Edgar Link	pending
a1015redlineamendmentnum.htm	Edgar Link	pending
a1015redlineamendmentnum001.jpg	Edgar Link	pending
a1015redlineamendmentnum002.jpg	Edgar Link	pending
a1015redlineamendmentnum003.jpg	Edgar Link	pending
a1015redlineamendmentnum004.jpg	Edgar Link	pending
a1015redlineamendmentnum005.jpg	Edgar Link	pending
a1015redlineamendmentnum006.jpg	Edgar Link	pending
a1015redlineamendmentnum007.jpg	Edgar Link	pending
a1015redlineamendmentnum008.jpg	Edgar Link	pending
a1015redlineamendmentnum009.jpg	Edgar Link	pending
a101redlineplatformlicen.htm	Edgar Link	pending
a101redlineplatformlicen001.jpg	Edgar Link	pending
a101redlineplatformlicen002.jpg	Edgar Link	pending
a101redlineplatformlicen003.jpg	Edgar Link	pending
a101redlineplatformlicen004.jpg	Edgar Link	pending
a101redlineplatformlicen005.jpg	Edgar Link	pending
a101redlineplatformlicen006.jpg	Edgar Link	pending
a101redlineplatformlicen007.jpg	Edgar Link	pending
a101redlineplatformlicen008.jpg	Edgar Link	pending
a101redlineplatformlicen009.jpg	Edgar Link	pending
a101redlineplatformlicen010.jpg	Edgar Link	pending
a101redlineplatformlicen011.jpg	Edgar Link	pending
a101redlineplatformlicen012.jpg	Edgar Link	pending
a101redlineplatformlicen013.jpg	Edgar Link	pending
a101redlineplatformlicen014.jpg	Edgar Link	pending
a101redlineplatformlicen015.jpg	Edgar Link	pending
a101redlineplatformlicen016.jpg	Edgar Link	pending
a101redlineplatformlicen017.jpg	Edgar Link	pending
a101redlineplatformlicen018.jpg	Edgar Link	pending
a101redlineplatformlicen019.jpg	Edgar Link	pending
a101redlineplatformlicen020.jpg	Edgar Link	pending
a101redlineplatformlicen021.jpg	Edgar Link	pending
a101redlineplatformlicen022.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lgnd-20180630.xml	Edgar Link	completed
lgnd-20180630.xsd	Edgar Link	pending
lgnd-20180630_cal.xml	Edgar Link	unprocessable
lgnd-20180630_def.xml	Edgar Link	unprocessable
lgnd-20180630_lab.xml	Edgar Link	unprocessable
lgnd-20180630_pre.xml	Edgar Link	unprocessable
lgnd-6301810q.htm	Edgar Link	pending
lgnd_63018exhibit311.htm	Edgar Link	pending
lgnd_63018exhibit312.htm	Edgar Link	pending
lgnd_63018exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

2018 Q2 Form 10-Q Financial Statement

#000088616318000113 Filed on August 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND LIGAND PHARMACEUTICALS INC Stock $lgnd

2018 Q2 Form 10-Q Financial Statement

#000088616318000113 Filed on August 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd